Patents by Inventor Jane Withnall

Jane Withnall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process
    Publication number: 20160002261
    Abstract: Processes for the preparation of the compound of formula II and intermediate compounds for use in the processes.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 7, 2016
    Inventors: Neil Barnwell, Philip Cornwall, Duncan Michael Gill, Gareth P. Howell, Rebecca Elizabeth Meadows, Eric Merifield, Christopher William Mitchell, Andiappan Murugan, Philip O Keefe, Zakariya Mohamed Patel, James Barry Rose, John Singleton, Jane Withnall
  • PROCESS
    Publication number: 20140364601
    Abstract: Processes for the preparation of the compound of formula (II) and intermediate compounds for use in the processes.
    Type: Application
    Filed: May 11, 2012
    Publication date: December 11, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Neil Barnwell, Philip Cornwall, Duncan Michael Gill, Gareth P. Howell, Rebecca Elizabeth Meadows, Andiappan Murugan, Philip O'Keefe, John Singleton, Jane Withnall, Eric Merifield, Christopher William Mitchell, Zakariya Mohamed Patel, James Barry Rose
  • Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
    Patent number: 8304417
    Abstract: The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such as a difumarate salt and a trihydrate and to pharmaceutical compositions containing such crystalline forms.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: November 6, 2012
    Assignee: AstraZeneca AB
    Inventors: James Gair Ford, James Francis McCabe, Anne O'Kearney-McMullan, Simon Mark Pointon, Lyn Powell, Philip O'Keefe, Mark Purdie, Jane Withnall
  • Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide
    Patent number: 8058294
    Abstract: A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: November 15, 2011
    Assignee: AstraZeneca AB
    Inventors: Robert Whittock, Jane Withnall
  • Salts 668
    Publication number: 20100093813
    Abstract: A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).
    Type: Application
    Filed: February 6, 2008
    Publication date: April 15, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Robert Whittock, Jane Withnall
  • Salts of a Selective Beta-2 Andrenoceptor Agonist
    Publication number: 20100016388
    Abstract: A pharmaceutically acceptable salt of 7-[(1R)-2-({2-[3-{[2-(2-Chlorophenyl)ethyl]amino}propyl)thio]ethyl}amino)-1-hydroxyethyl]-4-hydroxy-1,3-benzothia-zol-2(3H)-one provided it is not the ditrifluoroacetate, dihydrobromide or di-acetate salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).
    Type: Application
    Filed: February 29, 2008
    Publication date: January 21, 2010
    Inventors: Robert Whittock, Jane Withnall
  • Chemical Process
    Publication number: 20090099196
    Abstract: The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such as a difumarate salt and a trihydrate and to pharmaceutical compositions containing such crystalline forms.
    Type: Application
    Filed: December 14, 2005
    Publication date: April 16, 2009
    Inventors: James Gair Ford, James Francis McCabe, Anne O'Kearney-McMullan, Simon Mark Pointon, Lyn Powell, Philip O'Keefe, Mark Purdie, Jane Withnall
  • Salts 668
    Publication number: 20080249145
    Abstract: A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).
    Type: Application
    Filed: February 7, 2008
    Publication date: October 9, 2008
    Inventors: Robert Whittock, Jane Withnall